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ABSTRACT
Bone metastasis is a frequent occurrence in prostate cancer patients and often is 
lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. 
More effective models and treatment methods are required to improve the outcome 
of prostate cancer patients. In the present study, the effects of tumor-targeting 
Salmonella typhimurium A1-R were analyzed in vitro and in vivo on prostate cancer 
cells and experimental bone metastasis. Both ZOL and S. typhimurium A1-R inhibited 
the growth of PC-3 cells expressing red fluorescent protien in vitro. To investigate the 
efficacy of S. typhimurium A1-R on prostate cancer experimental bone metastasis, we 
established models of both early and advanced stage bone metastasis. The mice were 
treated with ZOL, S. typhimurium A1-R, and combination therapy of both ZOL and S. 
typhimurium A1-R. ZOL and S. typhimurium A1-R inhibited the growth of solitary bone 
metastases. S. typhimurium A1-R treatment significantly decreased bone metastasis 
and delayed the appearance of PC-3 bone metastases of multiple mouse models. 
Additionally, S. typhimurium A1-R treatment significantly improved the overall 
survival of the mice with multiple bone metastases. The results of the present study 
indicate that S. typhimurium A1-R is useful to prevent and inhibit prostate cancer 
bone metastasis and has potential for future clinical use in the adjuvant setting.
INTRODUCTION
Prostate cancer is diagnosed in more than 500,000 
men worldwide [1]. Bone metastases from prostate 
cancer can cause chronic pain, hypercalcemia, pathologic 
fractures, and nerve compression [2]. Zoledronic acid 
(ZOL), a bisphosphonate, has been used to prevent 
the development of metastatic bone lesions. Although 
bisphosphonates, irradiation, and surgical resection of 
tumors are used as treatments of bone metastases, the 
outcomes of the treatments are still unsatisfactory. 
Salmonella typhimuium (S. typhimurium) A1-R, is a 
genetically-engineered strain of Salmonella that is able to 
specifically target cancer cells [3]. S. typhimurium A1-R 
was able to inhibit or eradicate primary and metastatic 
tumors as monotherapy in nude mouse models of 
prostate [3, 4], breast [5-7], lung [8, 9], pancreatic [10-
14], ovarian [15, 16], stomach [17] and cervical cancer 
[18], as well as sarcoma [19-23] and glioma [24, 25], all 
of which are highly aggressive tumor models. Tumors 
with a high degree of vascularity were more sensitive to 
S. typhimurium A1-R, and vascular destruction appears to 
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play a role in S. typhimurium A1-R antitumor efficacy [25]. 
Tumor vessel destruction and tumor-growth inhibition 
were enhanced by primer dosing of S. typhimurium A1-R 
in immunocompetent transgenic mice expressing the 
nestin-driven green fluorescent protein (ND-GFP), which 
is selectively expressed in nascent blood vessels [26]. 
In the present study, the efficacy of S. typhimurium 
A1-R and the combination of S. typhimurium A1-R and 
ZOL was assessed in nude mice models of solitary and 
multiple bone metastases of prostate cancer. 
RESULTS AND DISCUSSION
Efficacy of S. typhimurium A1-R on human 
prostate cancer cells in vitro
To determine the efficacy of A1-R on prostate cancer 
cells, PC-3-RFP cells were incubated in 35 mm dishes for 
24 h, and the cells were treated with S. typhimurium A1-R 
for 1 h. The cells were observed with a Fluoview FV1000 
confocal microscope (Olympus Corp., Tokyo, Japan). 
Fluorescence imaging demonstrated that S. typhimurium 
A1-R expressing GFP selectively invaded and replicated 
intracellularly and killed PC-3-RFP cells (Figure 1). 
Clonogenic assays demonstrated that S. typhimurium 
A1-R inhibited proliferation of PC-3-RFP cells in a dose-
dependent manner (Figure 2). 
Efficacy of S. typhimurium A1-R therapy on a 
mouse model of multiple bone metastasis
Nude mice were injected in the left ventricle with 
PC-3-GFP cells (5 × 105). One week after intracardiac 
injection, half of the mice were treated once a week for 
3 weeks with an i.v. injection of S. typhimurium A1-R 
(5 × 107 CFU) (Figure 3a). Time-course fluorescence 
imaging of the study mice revealed GFP-expressing tumor 
growth in the control group and little tumor growth in the 
S. typhimurium A1-R group (Figure 3b). S. typhimurium 
A1-R significantly improved the metastasis-free survival 
and overall survival of the mice (Figure 3c, 3d). 
Figure 1: Efficacy of S. typhimurium A1-R in vitro on prostate cancer cells. PC-3-RFP cells were incubated in 35 mm dishes for 24 
h. The cells were treated with S. typhimurium A1-R for 1 h. The PC-3-RFP cells were rinsed with PBS and the cells were observed with 
the FV1000 confocal microscope. Fluorescence images were obtained at 24 hours after infection and demonstrated that S. typhimurium 
A1-R expressing GFP invaded a. and replicated intracellularly b. in PC-3-RFP cells. After the invasion and replication of GFP-expressing 
S. typhimuium A1-R, the infected cells shrunk c. and fragmented d.. See Materials and Methods for details. 
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Efficacy of S. typhimurium A1-R on a mouse 
model of solitary bone metastasis of prostate 
cancer
PC-3-RFP (5 × 105) cells were injected into the 
intramedullary cavity of the tibia in nude mice (Figure 4a). 
One week after the injection, the mice were divided into 
4 groups: a control group, a ZOL group, an A1-R group, 
and a ZOL+ S. typhimurium A1-R group. ZOL-group mice 
were treated with subcutaneous injection of ZOL (120 mg/
kg) (Sigma-Aldrich. St. Louis, MO) 5 times a week for 
4 weeks (Figure 4b). S. typhimurium A1-R group mice 
were treated with weekly i.v. injections of S. typhimurium 
A1-R (5 × 107 CFU) for a total of 3 weeks. ZOL+ S. 
typhimurium A1-R-group mice were treated with both s.c. 
injection of ZOL and i.v. injection of S. typhimurium A1-R 
at the same dosages listed above. Fluorescence imaging 
was performed with an iBOX Scientia Imaging System 
(UVP, LLC, Upland, CA) every week. The fluorescence 
images demonstrated that the control group had rapid 
growth of metastatic bone cancer, whereas the ZOL group, 
S. typhimurium A1-R group, and the ZOL+S. typhimurium 
A1-R group mice had reduced metastatic growth (Figure 
4c). The fluorescent tumor area of the control-group mice 
was 54.9 ± 6.1 mm2, ZOL group at 4 weeks mice was 
29.1 ± 9.2 mm2, S. typhimurium A1-R-group mice was 
23.8 ± 6.1 mm2, and ZOL+ S. typhimurium A1-R group 
mice was 18.4 ± 5.3 mm2 (Figure 4d). The S. typhimurium 
A1-R group and the ZOL+ S. typhimurium A1-R group 
had significant inhibition of tumor growth compared to 
the control group. Four weeks after the injection of cancer 
cells, the mice were sacrificed and tumor weight was 
measured. Tumor weights of the control group was 2.6 ± 
0.6 g; ZOL group was 0.5 ± 0.2 g; S. typhimurium A1-R 
group was 1.1 ± 0.6; and ZOL+ S. typhimurium A1-R 
group mice at 4 weeks was 0.3 ± 0.1 g (Figure 4e). 
The tumor targeting of prostate cancer-bone 
metastasis strategy, developed in the present report, could 
also be used with previously-developed tumor targeting 
strategies [27-34].
The present study demonstrates that S. typhimuium 
A1-R could significantly inhibit or prevent prostate cancer 
metastasis in the bone. These results indicate a promising 
approach to a currently highly treatment-resistant disease. 
Figure 2: Growth inhibitory effect of A1-R in vitro. Clonogenic assays were performed as previously described [40]. PC-3-RFP 
cells 1 × 103 were incubated in 35 mm dishes. PC-3-RFP colonies were fixed with methanol and stained with 1% crystal violet 8 days 
after zoledronic acid (ZOL) or S. typhimuium A1-R (1 × 107 or 1 × 108 CFU/dish). PC-3-RFP cells were plated in 35 mm dishes. ImageJ 
(National Institutes of Health, Bethesda, Maryland, USA) was used to quantify the areas of the colonies of the cells. a. Colonies after 
treatment with ZOL or S. typhimuium A1-R. b. PC-3-RFP colony area decreased after treatment with ZOL or S. typhimuium A1-R. ZOL 
inhibited the growth of PC-3-RFP cells compared to the untreated control group. S. typhimuium A1-R also inhibited the growth of PC-3-
RFP cells in a dose-dependent manner (*p < 0.05, **p < 0.01).
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Figure 3: Efficacy of S. typhimurium A1-R on multiple bone metastasis. a. PC-3-GFP cells were injected into the left ventricle in nude 
mice. On day 7, 14, and 21, S. typhimurium A1-R (5×107 CFU/mouse) was administered i.v.. Fluorescence imaging was performed every 
week. Metastasis-free survival and overall survival of mice treated with S. typhimurium A1-R or untreated controls was determined using 
the Kaplan-Meier method with the log-rank test. b. Time-course fluorescence imaging of prostate cancer bone metastasis with or without 
treatment of S. typhimuium A1-R. PC-3-GFP cells were inoculated into the left cardiac ventricle of nude mice. Fluorescence imaging 
visualized the progression of metastases in control mice. In contrast, there was only a small increase in fluorescence in the mice treated with 
S. typhimuium A1-R. c. Metastasis-free survival. d. Overall survival. 
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MATERIALS AND METHODS
Cell culture
PC-3 cells, which were originally established from 
metastatic bone lesions of human prostate cancer [35], 
were labeled with GFP or RFP. PC-3-RFP and PC-3-GFP 
cells were generated as previously described [36-39]. 
Cells were maintained in RPMI 1640 with 10% FBS + 1% 
penicillin streptomycin solution. Cells were subcultured 
for at least 3 passages before harvesting at their linear 
growth phase (approximately 70-80% confluent) for 
intracardiac or intramedullaly injection at 5 × 105 cells/
mouse. 
Animal care
Athymic nude mice (nu/nu) (AntiCancer Inc, San 
Diego, CA) were used in this study. Mice were maintained 
in a barrier facility of high efficiency particulate air-filtered 
racks. The animals were fed an autoclaved laboratory 
rodent diet. Animal experiments were performed in 
accordance with the Guidelines for the Care and Use of 
Laboratory Animals under National Institutes of Health 
assurance number A3873-01. 
Preparation of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer Inc., San Diego, CA, USA) were grown 
overnight on LB medium (Fisher Sci., Hanover Park, IL, 
Figure 4: Efficacy of S. typhimurium A1-R on solitary bone metastasis. a. A 5 mm midline skin incision was made to expose the tibial 
tuberosity. PC-3-RFP cells (5 × 105) in Matrigel (5 µl) (BD Bioscience, San Jose, CA) were injected in the intramedullary cavity of the tibia. 
b. One week after intratibial injection, fluorescence imaging was performed to confirm the growing RFP-expressing tumor using the iBOX 
Scientia Small Animal Imaging System (UVP LLC, Upland, CA, USA). The S. typhimuium A1-R group was administered S. typhimurium 
A1-R (5 × 107 CFU, i.v.) once a week for 3 weeks. The control group was administered the same volume of PBS. Fluorescence imaging 
was performed on treated and untreated mice. RFP fluorescent area was recorded every week for 5 weeks using the iBOX. c. Time-course 
imaging of the RFP-expressing bone tumors in the mouse model of solitary bone metastasis after treatment with ZOL and S. typhimuium 
A1-R. d. Fluorescence area of bone tumors in the control group and A1-R group mice. *p < 0.05, ** p < 0.01 compared with the control 
group. e. Tumor weight at the end of the experiment in mice injected intratibially with PC-3-RFP cells. Data are expressed as the mean ± 
SE. Differences between groups were analyzed with ANOVA. * p < 0.05 compared with the untreated control group.
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USA) and then diluted 1:10 in LB medium. Bacteria were 
harvested at late-log phase, washed with PBS, and then 
diluted in PBS [3, 5].
S. typhimurium A1-R killing of prostate cancer 
cells in vitro
PC-3-RFP cells were plated in 35 mm dishes (5 × 
102 cells/dish). S. typhimurium A1-R-GFP was added to 
the cancer cells (1 × 107 or 1 × 108 CFU/dish). After 1 h 
incubation at 37°C, the cells were rinsed and cultured in 
medium containing gentamycin sulfate (100 µg/ml) to kill 
external but not internal bacteria. Invasion and destruction 
of PC-3-RFP cells by S. typhimurium A1-R-GFP was 
visualized with a Fluoview FV1000 confocal microscope 
(Olympus Corp., Tokyo, Japan). Eight days after treatment 
with S. typhimurium A1-R, PC-3-RFP colonies were 
fixed in methanol and stained with 1% crystal violet as 
previously described [40]. ImageJ (National Institute of 
Mental Health, Bethesda, Maryland, USA) was used to 
quantify the area of the colonies of the cells. 
Efficacy of S. typhimurium A1-R therapy on a 
mouse model of multiple bone metastases
PC-3-GFP cells (5 × 105) were injected intracardially 
in nude mice. One week after injection, mice (treatment 
group) were administered S. typhimurium A1-R (5 × 107 
CFU, i.v.) once a week for 3 weeks. The remaining mice 
(control group) were administered the same volume of 
PBS. To evaluate metastasis-free survival, GFP-expressing 
lesions were initially observed using the Illumatool 
imaging system(Lighttools Research, Encinitas, CA) every 
2 days. Metastasis-free survival was defined as the time 
from intracardiac injection of cancer cells to the time of 
detection of bone metastases with the Illumatool. 
Efficacy of S. typhimurium therapy on a mouse 
model of solitary bone metastases
A midline skin incision (5 mm) was made just 
below the knee joint to expose the tibial tuberosity 
(Figure 4a). Matrigel (5 µL) (BD Bioscience, San Jose, 
CA) and PC-3-RFP cells (5 × 105) were co-injected into 
the intramedullary cavity of the tibia with a 1.0 mL 28 
G latex-free insulin syringe (BD and Company, Franklin 
Lakes, NJ). The skin was closed with a 6-0 suture. One 
week after injection, fluorescence imaging was performed 
to confirm the RFP-expressing tumor was growing, using 
the iBOX Scientia (UVP LLC, Upland, CA). The study 
mice were randomly divided into the following groups: 
control group; ZOL group; S. typhimuium A1-R group; 
and ZOL+ S. typhimuium A1-R-group. In the ZOL group, 
mice were treated with subcutaneous injection of 120 
mg/kg ZOL for 5 times a week for 4 weeks (Figure 4b). 
S. typhimuium A1-R-group mice were administered S. 
typhimurium A1-R (5 × 107 CFU, i.v.) once a week for 
3 weeks. ZOL+ S. typhimuium A1-R-group mice were 
administered both treatments. Fluorescence imaging 
was performed on treated and untreated mice, and GFP-
expressing areas were recorded every week for 5 weeks 
using the iBOX. At the end of the follow-up, the mice 
were sacrificed and the metastatic tumors were excised. 
Tumor weight was compared to evaluate the efficacy of 
ZOL and S. typhimuium A1-R. 
Statistical analysis
Data showing comparisons among 3 or more groups 
were assessed using analysis of variance (ANOVA). The 
Kaplan-Meier method was used for bone metastasis-free 
survival and overall survival. Log-rank tests were used for 
statistical significance of the difference between the two 
groups. Differences were considered significant when p < 
0.05. Data are expressed as mean ± SE. Statistical analyses 
were performed with EZR (Saitama Medical Center, Jichi 
Medical University). 
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